Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
174 stopped studies mapped to T-Cell Non-Hodgkin Lymphoma and descendants · 84% state a reason
Over the 174 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01738594 | Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell… | Phase 1 | terminated | Nov 30, 2012 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory… | Phase 1 | withdrawn | Dec 14, 2017 | City of Hope Medical Center | contract not executed | Other (stated, no rule matched) |
| NCT01948180 | Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma(CITADEL) | Phase 2 | terminated | Sep 23, 2013 | Cell Medica Ltd | Insufficient enrollment rate | Enrollment / accrual |
| NCT02061449 | Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | Phase 1 | terminated | Feb 12, 2014 | NYU Langone Health | Low Accrual | Enrollment / accrual |
| NCT02556463 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With… | Phase 1 | terminated | Sep 22, 2015 | MedImmune LLC | Company strategy | Sponsor / business decision |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT00038883 | Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00958074 | Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma | Phase 2 | terminated | Aug 13, 2009 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT01663571 | STAT3 in T Cells: At The Crossroads of Inflammation and Cancer | — | terminated | Aug 13, 2012 | NYU Langone Health | Study is permanently closed to enrollment .Collection of private identifiable information is… | Enrollment / accrual |
| NCT02359162 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat… | Phase 3 | terminated | Feb 9, 2015 | Sun Yat-sen University | The study is out of date | Other (stated, no rule matched) |
| NCT02533323 | P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens | Phase 2 | terminated | Aug 26, 2015 | Sun Yat-sen University | not stated | Not stated |
| NCT03235869 | Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma | Early Phase 1 | withdrawn | Aug 1, 2017 | University of Michigan Rogel Cancer Center | The company pulled durvalumab from heme malignancies | Sponsor / business decision |
| NCT00354107 | Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent… | Phase 1 / Phase 2 | terminated | Jul 20, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03205891 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin… | Phase 1 | withdrawn | Jul 2, 2017 | M.D. Anderson Cancer Center | Change in treatment priorities for these disease types as well as staffing concerns. | Other (stated, no rule matched) |
| NCT02875002 | Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive… | Phase 1 | withdrawn | Aug 22, 2016 | Yale University | not stated | Not stated |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | Phase 1 / Phase 2 | terminated | Aug 24, 2010 | Stanford University | Business decision by funding source | Funding |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT00985140 | Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides | — | terminated | Sep 28, 2009 | Stanford University | Competing studies | Other (stated, no rule matched) |
| NCT00082017 | UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas | Phase 2 | terminated | Apr 28, 2004 | National Cancer Institute (NCI) | IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND. | Enrollment / accrual |
| NCT01625455 | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary… | Phase 4 | terminated | Jun 21, 2012 | Vanderbilt University Medical Center | Difficulty recruiting. | Enrollment / accrual |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte… | Phase 2 | terminated | Aug 7, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01878708 | A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell… | Early Phase 1 | terminated | Jun 17, 2013 | Dana-Farber Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT01841021 | Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma… | N/A | terminated | Apr 26, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual, loss of sponsor support | Enrollment / accrual |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | Phase 2 | terminated | Jul 10, 2012 | Adam Lerner | Poor enrollment | Enrollment / accrual |
| NCT02487316 | A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | Phase 4 | withdrawn | Jul 1, 2015 | Jun Zhu | not stated | Not stated |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | Phase 2 | terminated | Mar 13, 2014 | University of Rochester | Lack of accrual | Enrollment / accrual |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With… | Phase 1 / Phase 2 | withdrawn | Sep 27, 2005 | Stanford University | not stated | Not stated |
| NCT02757248 | Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | Phase 1 | withdrawn | May 2, 2016 | Anne Beaven, MD | Boehringer Ingelheim is discontinuing their volasertib development program | Other (stated, no rule matched) |
| NCT00278265 | Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic… | Phase 2 | terminated | Jan 18, 2006 | German CLL Study Group | slow recruitment | Enrollment / accrual |
| NCT02808091 | Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T…(Gifox-B) | Phase 2 | terminated | Jun 21, 2016 | National Cancer Centre, Singapore | Slow recruitment | Enrollment / accrual |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT01556828 | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | — | terminated | Mar 16, 2012 | Stanford University | not stated | Not stated |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT00310128 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in… | Phase 2 | withdrawn | Apr 3, 2006 | AIDS Malignancy Consortium | Drug supply unavailable | Drug supply |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous…(PXD101-CLN-6) | Phase 2 | terminated | Jan 11, 2006 | Valerio Therapeutics | Enrollment stopped prior to reaching expected number of patients, study had accumulated sufficient… | Enrollment / accrual |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular… | Phase 2 | terminated | Aug 15, 2006 | National Cancer Institute (NCI) | Study terminated due to low accrual and the investigator left the NIH. | Investigator |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | withdrawn | May 1, 2013 | Stefan Schieke MD | not stated | Not stated |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | Phase 1 / Phase 2 | terminated | Aug 11, 2005 | University of Michigan | Slow enrollment | Enrollment / accrual |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00365274 | SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic… | Phase 2 | terminated | Aug 17, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00863395 | Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma(CTCL) | Phase 1 / Phase 2 | terminated | Mar 18, 2009 | University of Minnesota | not stated | Not stated |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | Phase 1 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 29, 2019source: clinicaltrials